REMASTER Study in Phoenix: What to Know About SPMS Research

10/24/2026 | Blog Bot | Uncategorized

Secondary progressive multiple sclerosis (SPMS) can raise questions that are difficult to answer from a search result alone. A person may notice gradual changes in walking, endurance, hand function, balance, cognition, or other daily activities and wonder how those changes fit into their MS journey. They may also hear about research studies and want to know what an opportunity actually involves before making a call. Arizona Neuroscience Research (ANR) in Phoenix lists the REMASTER study as an upcoming local research opportunity for adults with SPMS.

This article explains the information ANR currently provides about REMASTER, how to think through a research inquiry, and which questions can help you decide whether to ask for more information. It does not provide medical advice or determine eligibility. A clinical study can have detailed criteria, and only the ANR research team can confirm its current local status, screening requirements, and whether it may be appropriate to discuss.

Understanding secondary progressive multiple sclerosis

Multiple sclerosis can affect the central nervous system, including the brain and spinal cord. Symptoms and disease patterns differ from one person to another. Secondary progressive MS describes a form of MS in which disability may gradually worsen over time after an earlier relapsing course. Some people may still have activity or relapses, while others may experience progression with fewer obvious relapses. Language such as “secondary progressive,” “active,” and “non-active” has clinical meaning, so your treating neurologist is the right person to explain how it relates to your own history.

Living with SPMS often requires attention to the details that do not fit neatly into a checklist. A person may notice that a familiar route takes more energy, that a foot drags after a certain distance, or that heat, sleep, pain, stress, or infection changes how symptoms feel. Those observations do not diagnose a change by themselves, but they can be useful information to bring to a regular care visit or research discussion.

What ANR lists about the REMASTER study

Arizona Neuroscience Research lists REMASTER as study CLOU064P12301, a Phase 3 study evaluating remibrutinib in adults with secondary progressive MS. ANR describes the study as randomized, double-blind, and placebo-controlled, with a goal of assessing efficacy and safety. ANR’s current page says the Phoenix site is preparing to enroll participants. That wording matters: it means availability may not be the same as active screening today. Contact ANR directly for current timing and requirements rather than assuming that an inquiry guarantees a visit or enrollment.

REMASTER is a research study, not a promise of treatment or a substitute for regular MS care. Remibrutinib is under study in this setting. Before a person agrees to any research process, the site should explain the study’s purpose, procedures, potential risks, possible benefits, alternatives, and the voluntary nature of participation. A person can ask questions and can decide that the study is not a fit.

What a Phase 3 clinical study means

Study phases describe the stage of research, not the certainty of a result. A Phase 3 study is generally designed to gather additional evidence about an investigational approach in a larger group of people. It may look at outcomes, safety, side effects, laboratory information, and other measures specified in the research protocol. The study design helps researchers compare groups in a consistent way.

Randomized means eligible participants are assigned to study groups by a chance-based process. The participant does not choose the group.
Double-blind generally means the participant and much of the research team do not know the assignment during the blinded portion of the study. The consent materials explain the process and emergency safeguards.
Placebo-controlled means one group may receive a comparison product without the active investigational ingredient. A site can explain how assignment works and what the study schedule includes.
Protocol refers to the detailed plan that sets out visits, tests, safety monitoring, eligibility criteria, and study procedures.

These features protect the quality of the research, but they also mean research is different from receiving a chosen medication in routine care. No study can guarantee that someone will qualify, receive an investigational product, experience improvement, or avoid side effects. The right decision depends on a person’s goals, health history, practical needs, and conversation with their treating clinician and the research team.

When is it reasonable to ask ANR about REMASTER?

It can be reasonable to contact ANR if you are an adult with a diagnosis of SPMS and want current information about a local study. An inquiry is not a commitment. It is a way to ask whether the study is open, what the first step might look like, and whether the site needs records or other information before scheduling a screening conversation.

Public listings usually show only high-level criteria. The protocol may have additional requirements related to diagnosis documentation, previous or current treatments, timing of medications, medical history, laboratory values, imaging, reproductive considerations, other health conditions, or study logistics. Screening is designed to evaluate these factors carefully. Being interested in a study does not mean a person is eligible, and being ineligible for one study does not mean there are no other research or care options.

Helpful preparation for a screening discussion

Write down the date of your most recent neurology visit and the name of the practice that manages your MS care.
Keep an updated list of prescriptions, over-the-counter medicines, vitamins, and supplements.
Note recent symptoms, how often they occur, and how they affect work, mobility, self-care, sleep, or family responsibilities.
Ask the research team what records, imaging reports, or laboratory information they would like before an appointment.
Consider practical issues such as transportation, time away from work, caregiving, and whether a support person may attend.

Do not change, stop, or delay prescribed MS treatment in hopes of meeting study criteria unless your treating clinician directs you to do so. A research team can explain a study’s protocol, but your personal medical decisions should be made with the clinician who knows your health history.

Questions to ask about a possible REMASTER screening

People often find it easier to make a thoughtful decision when they write down their questions before contacting a research site. The following questions can help you start:

Is REMASTER actively screening or still preparing to enroll at the Phoenix location?
What is the purpose of the study, and what is remibrutinib being studied for?
What broad criteria does the site use before deciding whether to schedule a screening visit?
How many visits may be required, and which ones must be in person?
What examinations, laboratory work, questionnaires, or imaging may be part of the study?
How are study groups assigned, and what does placebo-controlled mean in this protocol?
What risks, discomforts, and possible benefits are described in the informed-consent document?
How will research care coordinate with my regular neurologist if I choose to participate?
Are study-related costs covered, and are there expenses I should plan for?
Who should I contact if I have a concern between study visits or decide to withdraw?

It is appropriate to ask for time to review consent materials. Informed consent is an ongoing conversation, not merely a form. It should explain what research is being done, what participation involves, known and unknown risks, privacy practices, alternatives to joining, contact information, and the right to leave the study. You can ask the team to explain a term in plain language before you decide.

How research fits alongside usual MS care

Clinical research does not replace regular medical care. Continue routine appointments and share relevant changes with the clinician who manages your MS. If you decide to explore a study, tell the research team about your treating neurologist and ask how communication will work. The site can explain what information is shared, what requires your permission, and who manages different concerns.

Symptoms can change for many reasons, including infection, medication effects, sleep disruption, pain, heat exposure, or a new neurological problem. Do not assume a new symptom is “just MS” or related to a study. For new or worsening nonemergency symptoms, contact your regular clinician or the study team promptly for individualized guidance.

Urgent symptoms need urgent care

Research screening is not emergency care. Call 911 or seek emergency evaluation for sudden stroke warning signs such as facial droop, speech difficulty, sudden severe weakness, new major vision loss, or a sudden severe headache unlike usual headaches. Seek immediate care for chest pain, severe trouble breathing, loss of consciousness, seizure activity, or another potentially life-threatening change. If you are enrolled in a study, follow the study’s emergency instructions as well, but do not delay emergency care while trying to reach a coordinator.

Local next steps for people in Phoenix

Arizona Neuroscience Research has Phoenix locations and welcomes inquiries from surrounding communities, including Scottsdale, Tempe, Mesa, Chandler, Gilbert, Glendale, Peoria, Paradise Valley, and nearby areas. To ask about REMASTER’s local status, begin with ANR’s Current Studies page and submit an inquiry through Volunteer Today. ANR’s blog also has general educational information about research participation.

ANR links the REMASTER study to the sponsor’s clinical-trial information and to ClinicalTrials.gov NCT07225504. Those sources can help you understand the public record, but they do not replace a site-specific conversation. Study status, availability, and screening requirements can change, and the ANR team can provide the most current local details.

Frequently asked questions about REMASTER in Phoenix

Is REMASTER enrolling now?

ANR currently describes its Phoenix location as preparing to enroll for REMASTER. Contact the research team to confirm whether screening is open and what the next step would be.

Is REMASTER for every person with MS?

No. ANR lists the study for adults with secondary progressive MS, and the protocol may include additional requirements. The research team makes eligibility determinations during screening.

Will participation guarantee access to remibrutinib or improve my symptoms?

No. The study is randomized, double-blind, and placebo-controlled. Research participation does not guarantee a specific assignment, benefit, or outcome.

Can I keep seeing my usual neurologist?

Clinical research is not a replacement for ongoing medical care. Ask the research team how study care and regular care can be coordinated if you choose to explore participation.

What if I decide research is not right for me?

Participation is voluntary. You can decline an inquiry, decide not to enroll after reviewing information, or discuss other care and research questions with your own neurology team.

A clear, careful way to learn more

For some people with SPMS, asking about research is a useful step toward understanding available options. For others, the details of a specific protocol may not fit their needs. Both outcomes are valid. If you want current local information about REMASTER, contact Arizona Neuroscience Research through the Volunteer Today page, ask about the study’s actual screening status, and bring questions that matter to your daily life and medical care.

Educational disclaimer: This article is general information about clinical research and is not medical advice, diagnosis, or treatment guidance. Study availability, eligibility, potential benefits, and risks must be discussed with the ANR research team and your own healthcare professionals. In an emergency, call 911.